Biogen Inc.
BIIB
$147.37
$3.602.50%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.68B | 9.61B | 9.67B | 9.66B | 9.84B |
| Total Other Revenue | -- | -- | -- | -20.70M | -39.60M |
| Total Revenue | 9.68B | 9.61B | 9.67B | 9.66B | 9.84B |
| Cost of Revenue | 2.22B | 2.26B | 2.28B | 2.37B | 2.53B |
| Gross Profit | 7.45B | 7.35B | 7.39B | 7.29B | 7.30B |
| SG&A Expenses | 2.38B | 2.31B | 2.49B | 2.48B | 2.50B |
| Depreciation & Amortization | 386.50M | 372.10M | 302.70M | 268.70M | 240.60M |
| Other Operating Expenses | 254.40M | 251.60M | 232.80M | 227.30M | 218.80M |
| Total Operating Expenses | 7.21B | 7.21B | 7.51B | 7.67B | 7.95B |
| Operating Income | 2.47B | 2.40B | 2.16B | 1.99B | 1.88B |
| Income Before Tax | 1.91B | 1.91B | 1.31B | 1.32B | 1.30B |
| Income Tax Expenses | 273.80M | 291.70M | 156.30M | 156.00M | 135.30M |
| Earnings from Continuing Operations | 1.63K | 1.61K | 1.16K | 1.17K | 1.16K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 800.00K | 1.00M | -700.00K | -400.00K |
| Net Income | 1.63B | 1.62B | 1.16B | 1.17B | 1.16B |
| EBIT | 2.47B | 2.40B | 2.16B | 1.99B | 1.88B |
| EBITDA | 3.14B | 3.03B | 2.73B | 2.52B | 2.38B |
| EPS Basic | 11.21 | 11.11 | 7.97 | 8.05 | 8.03 |
| Normalized Basic EPS | 9.94 | 9.30 | 8.59 | 8.17 | 8.03 |
| EPS Diluted | 11.18 | 11.07 | 7.94 | 8.01 | 7.98 |
| Normalized Diluted EPS | 9.91 | 9.27 | 8.56 | 8.14 | 7.99 |
| Average Basic Shares Outstanding | 582.20M | 581.40M | 580.50M | 579.60M | 578.80M |
| Average Diluted Shares Outstanding | 584.00M | 583.60M | 582.30M | 581.90M | 581.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
